12:00 AM
 | 
Apr 29, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ACH-3102: Additional Phase IIa data

Data from all 8 treatment-naïve patients with HCV genotype 1b infection carrying the CC genotype of the interleukin-28B (IL-28B; IFNL3) gene in an open-label Phase IIa trial showed that oral ACH-3102 plus ribavirin for 12 weeks led to an SVR 4 weeks after the end of treatment in 5 patients. Achillion said 1 patient had a virologic...

Read the full 273 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >